hENT1 as a Predictive Biomarker in PDAC—Letter
Lenka N.C. Boyd(Amsterdam University Medical Centers), Geert Kazemier(European Organisation for Research and Treatment of Cancer), Hanneke W.M. van Laarhoven(Dutch Cancer Society), Mahsoem Ali(Amsterdam Neuroscience), Tessa Y. S. Le Large(Amsterdam University Medical Centers), Elisa Giovannetti(University of Pisa), Jisce R. Puik(Amsterdam UMC Location Vrije Universiteit Amsterdam), Laura L. Meijer(Erasmus MC)
Cited by 2
Related Papers
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial
|The Lancet. Gastroenterology & hepatology|2019|597
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|582
Analysis of Drug Interactions
|Methods in molecular biology|2011|252
White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer
|Nature Communications|2020|238